Medium-Term Weight Loss and Remission of Comorbidities Following Endoscopic Sleeve Gastroplasty: a Systematic Review and Meta-analysis

Obes Surg. 2023 Nov;33(11):3527-3538. doi: 10.1007/s11695-023-06778-x. Epub 2023 Sep 13.

Abstract

This systematic review and meta-analysis aimed to determine the short- and medium-term weight loss outcomes and comorbidity resolution following endoscopic sleeve gastroplasty. Our search identified 35 relevant studies containing data from 7525 patients. Overall, pooled short-term (12 months) total weight loss (TWL) was 16.2% (95% CI 13.1-19.4%) in 23 studies (n = 5659). Pooled medium-term TWL was 15.4% (95% CI 13.7-17.2%) in 10 studies (n = 4040). Diabetes resolution was 55.4% (95% CI 46-64%), hypertension resolution was 62.8% (95% CI 43-82%), dyslipidaemia resolution was 56.3% (95% CI 49-63%), and obstructive sleep apnoea resolution was 51.7% (95% CI 16.2-87.3%) in four studies (n = 480). This pooled analysis demonstrates that ESG can induce durable weight loss and resolution of obesity-associated comorbidities in patients with moderate obesity.

Keywords: Comorbidities; Endoscopic sleeve gastroplasty; Obesity; Weight loss.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Comorbidity
  • Gastroplasty*
  • Humans
  • Obesity / surgery
  • Obesity, Morbid* / surgery
  • Treatment Outcome
  • Weight Loss